Take a stand against Chronic Limb-Threatening Ischemia (CLTI) for your patients.

PTA avoids permanent implants, but it also has high acute recoil and dissection rates, especially in BTK lesions with calcification or long disease. This often leads to: 

• Suboptimal acute luminal gain 
• Early restenosis 
• Bailout stenting
   

Esprit provides temporary mechanical scaffolding to stabilize the vessel during healing and then fully resorbs, restoring vessel compliance and physiology. This gives you better early lumen durability than PTA, without the long-term penalty of a permanent implant. 

Bare-metal stents leave a permanent rigid cage, which: 

• Disrupts natural vessel motion 
• Promotes chronic inflammation 
• Increases neointimal hyperplasia 

Esprit delivers controlled drug elution (anti-proliferative therapy) during the highest restenosis risk period and then disappears, eliminating the long-term inflammatory stimulus. This combination targets restenosis both biologically and mechanically, unlike BMS which address neither optimally over time. 

No—this is actually one of Esprit’s strongest advantages. 

With bare-metal stents, future options are constrained by: 

• Metal layers 
• Difficult re-crossing 
• Limited surgical targets 

Because Esprit fully resorbs, it preserves:  

• Future endovascular access 
• Surgical bypass options 
• Repeat PTA or DCB use 

This is particularly important in CLTI patients, where disease progression and repeat interventions are expected. 

Esprit is engineered to provide sufficient radial strength during the critical healing window, then gradually resorb once the vessel has remodeled. Unlike early-generation scaffolds in other vascular beds, Esprit’s design is BTK-specific, accounting for:  

• Smaller vessel diameters 
• Lower flow states 
• Longer lesion lengths 

Clinical data to date show no signal of excess acute thrombosis when used per IFU and with standard antiplatelet therapy. 

Bare-metal stents permanently alter vessel compliance and can compromise bypass targets. Esprit restores vessel patency during healing and then leaves no metal behind, preserving distal targets and avoiding chronic inflammatory stimulus—key in CLTI patients with long life-time disease burden.

Esprit is designed to maintain radial strength through the biologically critical remodeling phase, then resorb after the vessel has stabilized. This avoids both early recoil and late chronic injury, which are common failure points for PTA and BMS respectively.